Previous 10 | Next 10 |
2023-10-08 06:29:00 ET Growth-oriented investors looking for stocks that can heat up their portfolios before the end of 2023 want to turn their attention to the healthcare sector. Upcoming binary events could soon send these two biotech stocks rocketing higher. The U.S. Food and Drug Ad...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present new results for patisiran, an investigational RNAi therapeutic in development for the treatment of the cardiomyopathy of transthyretin-mediated (ATTR) amyloidosis, ...
2023-10-05 16:53:53 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals: Game-Changing Discoveries In Healthcare Regeneron and Intellia expand gene editing partnership Regeneron nabs FDA priority review for lymphoma therapy For further details see:...
2023-09-29 15:00:29 ET More on the markets Historical Evidence Between Real Yields Suggests Further Slump For SPY Interest Rates Won't Be Higher For Longer: SPY Implications Rate environment today 'rhymes with 2008' - J.P. Morgan's Kolanovic Stocks in midst o...
2023-09-29 13:05:39 ET More on AbbVie, Alnylam, etc. AbbVie: Company Vs. Stock, A Gentle Facelift Would Be Nice (Technical Analysis) AbbVie Vs. AstraZeneca: Battle Of The Pharmaceutical Behemoths AbbVie Inc. (ABBV) Morgan Stanley 21st Annual Global Healthcare Brokers...
2023-09-15 14:04:22 ET More on Alnylam Pharmaceuticals Seeking Alpha’s Quant Rating on Alnylam Pharmaceuticals Historical earnings data for Alnylam Pharmaceuticals Financial information for Alnylam Pharmaceuticals Alnylam Continues To Deliver, But An U...
2023-09-14 11:20:00 ET More on Alnylam Pharmaceuticals Seeking Alpha’s Quant Rating on Alnylam Pharmaceuticals Historical earnings data for Alnylam Pharmaceuticals Financial information for Alnylam Pharmaceuticals Alnylam Continues To Deliver, But An U...
2023-09-13 17:00:37 ET More on Alnylam Pharmaceuticals Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatility Alnylam: Unlimited Promise Or Unlimited Losses? Alnylam succeeds in Phase 2 trial for blood pressure drug Seeking Alp...
– Cardiovascular and Renal Drugs Advisory Committee Voted 9:3 That the Benefits of Patisiran Outweigh its Risks for the Treatment of the Cardiomyopathy of ATTR Amyloidosis – – Prescription Drug User Fee Act Target Action Date is October 8, 2023 – Al...
2023-09-13 08:25:41 ET More on Alnylam Seeking Alpha’s Quant Rating on Alnylam Pharmaceuticals Historical earnings data for Alnylam Pharmaceuticals Financial information for Alnylam Pharmaceuticals Alnylam Continues To Deliver, But An Upcoming FDA Meet...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...